```
AND FEURLE PUDUSED PROGRESSIVE COMPASSIONAT
    ZTHCARE CHALLENGING LEADER INSPIRING EXCELLENCE
   SSIONATE PROFESSIONAL CUTTING EDGE FIRST TECHNOLOG
  ON TO DETAIL DILIGENT CARING DYNAMIC PEOPLE FOCUSE
  HEALTHCARE ETHICAL ACCURATE EFFICIENT CHALLENGIN
  PLE FOCUSED PROGRESSIVE COMPASSIONATE HEALTHCAF
  EFFICIENT CHALLENGING LEADER INSPIRING EXCELLENCE
  ASSIONATE PROFESSIONAL CUTTING EDGE FIRST TECHNOLOG
 N TO DETAIL DILIGENT CARING DYNAMIC HEALTHCARE PEOPL
 IST TECHNOLOGY ETHICAL ACCURATE EFFICIENT CHALLENGIN
  'LE FOCUSED PROGRESSIVE COMPASSIONATE PROFESSION/
  R HEALTHCARE INSPIRING EXCELLENCE ATTENTION TO DETA
  IONAL CUTTING EDGE FIRST TECHNOLOGY ETHICAL ACCURA
  LIGENT CARING DYNAMIC PEOPLE FOCUSED PROGRESSIV
  TE EFFICIENT CHALLENGING LEADER INSPIRING EXCELLENT
 ₹OGRESSIVE HEALTHCARE COMPASSIONATE PROFESSION
 ENGING LEADER INSPIRING EXCELLENCE ATTENTION TO DF
SSIONAL CUTTING EDGE FIRST TECHNIOLOGY ETHICAL ACC
```

LOGY ETHICAL ACCURATE EFFICIF
USED PROGRESSIVE COMPASSI
ARE LEADER INSPIRING EXCELL
ONAL CUTTING EDGE FIRST TECH
ENT CARING DYNAMIC PEOPLE I

ACCURATE EFFICIENT CHALLEN
RE PEOPLE FOCUSED PROGRESS

GING LEADER INSPIRING EXCELLA

^\*'^! CUTTING EDGE FIRST TECHNIC

'E EFFICIENT CHALLENGING LEADER INSPIRING EXCELLE ASSIONATE PROFESSIONAL CUTTING EDGE FIRST TECHNOLO ON TO DETAIL DILIGENT CARING DYNAMIC PEOPLE FOCUSE ECHNOLOGY ETHICAL ACCURATE EFFICIENT CHALLENGIN LE FOCUSED PROGRESSIVE COMPASSIONATE PROFESSIONA DER INSPIRING EXCELLENCE ATTENTION TO DETAIL DILIGEN TING EDGE FIRST TECHNOLOGY ETHICAL ACCURATE EFFICIEN NG DYNAMIC HEALTHCARE PEOPLE FOCUSED PROGRESSIV ICAL ACCURATE EFFICIENT CHALLENGING LEADER INSPIRIN ) GRESSIVE COMPASSIONATE PROFESSIONAL CUTTING EDG CELLENCE ATTENTION TO DETAIL DILIGENT CARING DYNAM ST TECHNOLOGY ETHICAL ACCURATE HEALTHCARE EFFICIEN DYNAMIC PEOPLE FOCUSED PROGRESSIVE COMPASSIONAL EFFICIENT CHALLENGING LEADER INSPIRING EXCELLENC SSIONATE PROFESSIONAL CUTTING EDGE FIRST TECHNOLOG N TO DETAIL DILIGENT CARING DYNAMIC PEOPLE FOCUSE THEARE ETHICAL ACCURATE EFFICIENT CHALLENGIN



# Q1 2020 Investor Presentation

As of 31 March 2020

#### **Disclaimer**



#### Disclaimer and important information in relation to this presentation

This presentation has been prepared solely for use as earnings presentation of Dr. Sulaiman Al Habib Medical Services Group Company (the "Company"). By attending or by reading this presentation, you agree to be bound by the following limitations.

The information contained in this presentation is for background purposes only and does not purport to be comprehensive and has not been independently verified, nor does it constitute or form part of any invitation or inducement to engage in any investment activity, nor does it constitute an offer or invitation to buy or subscribe for any securities in any jurisdiction, or a recommendation in respect of buying, holding or selling any securities.

No representation or warranty, express or implied, is made as to, and no reliance should be placed by any person for any purpose on the information contained in this presentation, fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation.

The information in this presentation is subject to change, update, revision, verification and amendment and such information may change materially. HMG is under no obligation to update or keep current the information contained in this presentation and any opinions expressed in it is subject to change without notice. This presentation has not been approved by any competent regulatory authority.


This presentation nor anything contained herein shall form the basis of, or be relied upon in connection with, any offer or commitment whatsoever in any jurisdiction. Any investor should make his investment decision, solely on the basis of the information that is contained in the prospectus (the "Prospectus") published by the "Company". The contents of this presentation are not to be construed as legal, or financial.

The distribution of this presentation may be restricted by law in certain jurisdictions and persons into whose possession any document or other information referred to herein come should inform themselves about and observe any such restriction. Any failure to comply with these restrictions may constitute a violation of the securities laws of any such jurisdiction.

This presentation may include statements that are, or may be deemed to be, "forward-looking statements" with respect to the Company's financial position, results of operations and business and certain of the Company's plans, intentions, expectations, assumptions, goals and beliefs. The contents of this presentation have been prepared by and are the sole responsibility of the Company.

# **Presenting team**











# **AGENDA**

Who we are

**How we performed** 

Spotlight

Addressing challenges

R Q&A

Appendix #1

**Summarized financials** 



# **Equity story and strategy**

A well-defined strategy enhanced by our core values




# Vision

To be the most trusted healthcare provider in medical excellence and patient experience globally

# Mission


To develop and operate state of the art medical facilities and provide innovative healthcare services to create value for people

#### Strengthening the core




Patient centric healthcare

### Expanding the reach



Organic growth while considering inorganic opportunities

#### **Broadening the service**



**Creation of new business lines** 

#### **Business structure**

A fully integrated healthcare services provider









### **Pharmacies**

### **HMG Solutions**


- 7 hospitals in Saudi Arabia and Dubai
- **1,900+** beds and **1,370+** clinics
- 1 medical center in Bahrain through management agreement
- **13k+** staff, **2,750+** physicians

- Outpatient pharmacies as part of the hospitals
- 13 pharmacies in Saudi Arabia
- •1 pharmacy in Dubai
- 400+ employees
- E-Pharmacy

- Cloud Solutions: technology Arms including HIS, e-medicine, mobile app & other Applications
- PPP Programs: Operating Intensive Care Units for others
- Home Healthcare services
- MD LAB for advance laboratory services

# Where we operate


With total built-up area of 689,000+ m2, HMG owns most of its hospital properties



## **Projects update**

Solidifying our market leadership through aggressive expansion













#### **South-West Jeddah**

2023E 50% ownership







2024E 100% ownership






270 Clinics



SAR 243.5 mn




SAR 1.5 bn Construction



# **Key messages**

#### A best-in-class healthcare leader with a clear growth strategy






#### **Best-in-class**

- Regional integrated healthcare provider with
   25 year track record
- Resilient revenues and stable gross margins supported by economies of scale, strong cash flow management and healthy balance sheet
- Defined strategy to strengthen core, expand reach and broadening the services



### Catalysts for value creation

- Technology: Pioneer in healthcare technology, award-winning hospital information system
- Robust expansion plan: 2 new hospitals under construction, construction of one additional hospital to start in 2021, expansion of HMG Solutions



### **Efficiency drivers**


- Efficient cash conversion cycle: shortest CCC in the industry, proactive collection process
- Cost efficiency: economies of scale and cost efficiency on a growing patient volume base
- Technology to drive operational efficiency: best in class HIS, patients and physicians apps and rapidly growing business solutions including special focus on automation of services





How we performed


# Highlights: Q1 2020




































# Financial performance highlights









# Healthy balance sheet










# Low leverage levels












### **Update: Covid-19 impact and response**





#### Situation remains fluid

- Government precautionary measures to limit and counter the outbreak, including curfews across the Kingdom. Some restrictions are now being lifted
- HMG facilities and subsidiaries remain operational with negative impact from the curfew
- Saudi government announced stimulus plan for private sector




#### **Expected impact**

- Could impact the Group's future financial results, cash flows and financial condition
- Impact being monitored on realtime basis to introduce mitigating actions
- Magnitude of the financial impact not yet known
- 3x scenarios as simulation for future material impact



### Mitigating actions

- Issuing of required curfew permits for operational teams on time to avoid service distribution in addition to enhance patient services
- The only private hospital provider to be licensed to perform COVID-19 test
- Increase readiness of **electronic service channels** by activating remote consultation services Live Care, e-pharmacy etc..
- Medicine delivery and home medical services including rapid response team
- Cost structure review including reducing overtime, reduced working hours allowances, work hours, supplier cost reductions, and revisited outsourced services and other operational costs
- Working on bank facilities as **additional working capital** in case crisis continues for longer than anticipated period



Q&A



# **Summary: Balance sheet**



SAR '000	2018	2019	Q1 2019	Q1 2020
Current assets	2,908,116	2,989,126	2,946,396	3,053,294
Inventory	302,537	295,867	279,274	361,758
Investments	43,488	40,032	45,049	39,240
Fixed assets	4,287,023	5,142,279	4,599,719	5,126,970
Other assets	_	-	_	-
Total assets	7,541,164	8,467,304	7,870,438	8,581,262
Current liabilities	1,364,162	1,495,280	1,471,696	1,438,801
Non-current liabilities	1,619,743	2,381,230	1,819,360	2,318,559
Other liabilities		-	-	
Shareholders' equity	4,328,022	4,393,877	4,350,606	4,636,446
Total liabilities and shareholders' equity	7,541,164	8,467,304	7,870,438	8,581,262
Minority interests	229,237	196,917	228,776	187,456

# **Summary: Income statement**



SAR '000	2018	2019	Q1 2019	Q1 2020
Revenue	4,587,633	5,016,280	1,227,903	1,343,343
Sales cost	(3,225,624)	(3,492,741)	(823,705)	(943,492)
Total income	1,362,009	1,523,539	404,198	399,851
Other revenues	99,199	63,515	18,140	16,798
Total revenues	1,461,208	1,587,054	441,507	416,649
Admin and marketing expenses	560,486	655,819	175,191	141,244
Other expenses	18,085	(4,674)	5,908	5,932
Total expenses	578,571	651,145	181,099	147,176
Net income before Zakat	882,637	935,909	260,408	269,473
Zakat	81,330	65,678	26,328	22,874
Net income	801,307	870,231	234,080	246,599

# **Summary: Cash flow statement**



SAR '000	2018	2019	Q1 2019	Q1 2020
Net income	881,404	903,273	259,947	259,856
Depreciation	200,187	255,919	56,307	78,068
Accounts receivable	271,418	(322,563)	7,836	243,894
Inventory	3,715	(29,372)	(13,826)	(65,838)
Prepaid expenses	(37,470)	(78,755)	8,518	15,794
Accounts payable	48,877	139,103	(4,055)	(52,488)
Other changes in operating activity	79,243	192,133	65,197	(2,875)
Purchases of fixed assets	(830,128)	(735,506)	(144,710)	(62,630)
Other changes in investing act.	10,454	4,198	(1,691)	1,000
Increase in debts	408,135	471,174	60,567	(60,423)
Other changes in financing act.	(807,254)	(972,061)	(162,597)	(18,190)
Cash at beginning of period	1,140,537	1,369,118	1,369,118	1,196,661
Cash at end of period	1,369,118	1,196,661	1,500,611	1,532,829

Dr. Sulaiman Al Habib Medical Services Group

**Tel:** +966 11 525 9999

Fax: +966 11 462 0096

**Mob:** +966 50 338 2785

Email: investor.relations@drsulaimanalhabib.com

P.O. Box 301578
Riyadh 11372, Kingdom of Saudi Arabia www.hmg.com

